Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting
Autore:
Chen, XG; Tang, J; White, PF; Wender, RH; Quon, R; Sloninsky, A; Naruse, R; Kariger, R; Webb, T; Norel, E;
Indirizzi:
Univ Texas, SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas,TX 75390 USA Univ Texas Dallas TX USA 75390 iol & Pain Management, Dallas,TX 75390 USA Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA Cedars Sinai Med Ctr Los Angeles CA USA 90048 , Los Angeles, CA 90048 USA
Titolo Testata:
ANESTHESIA AND ANALGESIA
fascicolo: 4, volume: 93, anno: 2001,
pagine: 906 - 911
SICI:
0003-2999(200110)93:4<906:TEOTOD>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PREVENT POSTOPERATIVE NAUSEA; INTRAVENOUS DOLASETRON; DOUBLE-BLIND; GYNECOLOGIC SURGERY; ONDANSETRON; PLACEBO; MULTICENTER; MESILATE; MESYLATE; ADMISSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: White, PF Univ Texas, SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd,F2208, Dallas, TX 75390 USA Univ Texas 5323 Harry Hines Blvd,F2208 Dallas TX USA 75390 0 USA
Citazione:
X.G. Chen et al., "The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting", ANESTH ANAL, 93(4), 2001, pp. 906-911

Abstract

Dolasetron (12.5 mg IV) is effective in both preventing and treating postoperative nausea and vomiting (PONV) after ambulatory surgery. However, the optimal timing of dolasetron administration and its effect on the patient'squality of life after discharge have not been established. One-hundred-five healthy, consenting women undergoing gynecologic laparoscopic procedures with a standardized general anesthetic technique were enrolled in this randomized, double-blinded study. Group I received dolasetron 12.5 mg IV 10-15 min before the induction of anesthesia; Group 2 received dolasetron 12.5 mgIV at the end of the laparoscopy (79 +/- 48 min later than Group 1); and Group 3 received dolasetron 12.5 mg IV at the end of anesthesia (93 +/- 52 min later than Group 1). The incidence of PONV, complete responses (defined as no emetic episodes and no rescue medication within the 24-h period afteranesthesia), recovery profiles, and patient satisfaction were recorded. Inthe postanesthesia care unit and during the 24-h follow-up period, the incidence of nausea and vomiting, as well as the need for rescue antiemetics, did not differ significantly among the three groups. The percentages of patients with complete responses to the study drug within the first postoperative 24 h were also similar in all three groups (55%, 59%, and 52% for Groups 1, 2, and 3, respectively). The early and intermediate recovery profiles,including resumption of a normal diet and patient satisfaction with the control of PONV, were not different among the three study croups. Dolasetron 12.5 mg IV administered before the induction of anesthesia is as effective as dolasetron given at the end of laparoscopy or at the end of anesthesia in preventing PONV after outpatient laparoscopy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 01:31:37